decernotinib (Hoock GmbH)
Structured Review
Decernotinib, supplied by Hoock GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/decernotinib/decernotinib/pm38898941-505-34-22
Average 90 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. Article Snippet: While several therapeutic options exist, the need for more effective, safe and convenient treatment for a variety of autoimmune diseases persists.. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies.. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. Article Title: Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review. Article Snippet: Journal of Article Title: Current and future status of JAK inhibitors Article Snippet: An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling in multiple disease states has led to an increasing applicability of therapeutic intervention with JAK inhibitors.. These agents have revolutionised treatments for a heterogeneous group of disorders, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel disease, and multiple immune-driven dermatological diseases, exemplifying rapid bench-to-bedside translation.. In this Therapeutics paper, we summarise the currently available data concerning the successes and safety of an array of JAK inhibitors and hypothesise on how these fields could develop. Article Title: Development of Selective Covalent Janus Kinase 3 Inhibitors Article Snippet: Fleischmann, R. M.; Article Title: Janus kinase inhibitors for rheumatoid arthritis. Article Snippet: Treatment of autoimmune diseases, such as rheumatoid arthritis (RA), has advanced substantially over the past decade with the development of biologics targeting inflammatory cytokines.. Recent progress in treating RA has been achieved with janus kinase (JAK) inhibitors (Jakinibs), an orally available disease-modifying anti-rheumatic drug targeting the intracellular kinase JAK and with similar efficacy to biologics.. The first Jakinib approved for RA was tofacitinib, which exerted superiority to methotrexate and non-inferiority to tumor necrosis factor (TNF) inhibitors. Article Title: Targeting cytokine signaling in autoimmunity: back to the future and beyond. Article Snippet: Cytokines represent structurally diverse soluble factors with critical roles in normal immune function and the pathogenesis of autoimmunity.. The emergence of many successful biological therapies targeting cytokines and cytokine receptors exemplifies the importance of cytokines in driving human autoimmune disease; unsurprisingly, there is no paucity of reviews on this subject.. Nonetheless, many patients with autoimmune disease do not respond to biologicals, and cure remains an unmet goal. Article Title: Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. Article Snippet: Fleischmann RM, Damjanov NS, Kivitz AJ, |
